Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Explaining subgroup findings using spline regression: Risk of kidney failure in patients with heart failure and normal kidney function receiving RAS inhibitors

Patel SS, Heidenreich PA, Morgan CJ, Faselis C, Zhang S, Wu WC, Lam PH, Palant CE, Zeng-Treitler Q, Fonarow GC, Ahmed A. Explaining subgroup findings[...]

Comprehensive echocardiogram evaluation with view primed vision language AI

Vukadinovic M, Chiu IM, Tang X, Yuan N, Chen TY, Cheng P, Li D, Cheng S, He B, Ouyang D. Comprehensive echocardiogram evaluation with view[...]

Differential Performance of Polygenic Score for Coronary Artery Disease Based on Coronary Artery Calcium Between Men Living With and Without HIV

Wojcik G, Arvanitis M, Haberlen S, Kim EY, Kim H, Nam K, Feinstein MJ, Wolinsky S, Margolick JB, Budoff M, Magnani JW, Duggal P, Post[...]